Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening

Ciatto, Stefano; Zappa, Marco; Villers, Arnauld; Páez, Álvaro; Otto, Suzie J.; Auvinen, Anssi

doi:10.1111/j.1464-410x.2003.04407.x

Cited by 60 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, the men using cholesterol-lowering medication are probably more active users of health services, which could result also in more frequent serum PSA determinations and digital rectal examinations. Because routine prostate cancer screening with the PSA test is not recommended in Finland and the prevalence of opportunistic screening is <20% annually (31), it is plausible that more latent prostate cancers are found among the medication users due to more active PSA testing compared with nonusers. This would falsely increase the observed OR of the overall prostate cancer for medication users and mask a possible protective effect of medication use.…”

Section: Discussionmentioning

confidence: 99%

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

Murtola

Tammela

Lahtela

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

167

155

View full text Add to dashboard Cite

Background: Previous studies have shown that statin use may reduce prostate cancer risk. In the current study, we evaluated the association between serum cholesterol -lowering medication use and prostate cancer risk at the population level. Materials and Methods: All newly diagnosed prostate cancer cases in Finland during 1995 to 2002 and matched controls (24,723 case control pairs) were identified from the Finnish Cancer Registry and the Population Register Center, respectively. Detailed information on cholesterol-lowering drug purchases during the study period was obtained from the prescription database of the Social Insurance Institution of Finland. Results: After adjustment for potential confounders, having ever-use of any statin was associated with mar-

show abstract

Section: Discussionmentioning

confidence: 99%

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

Murtola

Tammela

Lahtela

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

167

155

View full text Add to dashboard Cite

show abstract

“…If the latter, then an inverse association with total prostate cancer should have been observed in the Finnish study with the low prevalence of PSA testing (7% in 1996 and 14% in 1999; ref. 21) versus >70% in the three U.S. cohorts. To the contrary, a very weak positive association was noted for statins and total prostate cancer (odds ratio, 1.07; 95% confidence interval, 1.00-1.13), the confidence interval for which was not compatible with an inverse association.…”

Section: Introductionmentioning

confidence: 99%

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Platz¹

2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

“…In the Prostate, Lung, Colorectal and Ovarian (PLCO) trial about half of the patients in the screening group had already been tested at least once with either PSA or DRE (3). In the European Randomized Study of Screening for Prostate Cancer (ERSPC), contamination was lower (ranging from 8.6% to 36.6%) (4,22). Regarding pre-screened men rates, in our study illiterate men had lower probability to have had a previous prostatic evaluation compared with more educated patients.…”

Section: Discussionmentioning

confidence: 65%

Association between Literacy, Compliance with Prostate Cancer Screening, and Cancer Aggressiveness: Results from a Brazilian Screening Study

et al. 2013

View full text Add to dashboard Cite

Purpose: Little is known about the effects of literacy levels on prostate cancer screening. This study evaluates the association between literacy, compliance with screening, and biopsy findings in a large Brazilian screening study. Materials and Methods:We analyzed 17,571 men screened for PCa with digital rectal examination (DRE) and total and free prostate-specific antigen (PSA) from January 2004 to December 2007. Of those, 17,558 men had information regarding literate status. Full urological evaluation in a specialized cancer center was recommended in the case of: a) suspicious DRE, b) PSA > 4.0 ng/mL, or c) PSA 2.5-3.9 ng/mL and free/total PSA (f/tPSA) ratio < 15%. Transrectal ultrasound guided prostate biopsy (14 cores) was performed upon confirmation of these findings after the patient's consent. Patients' compliance with screening recommendations and biopsy results were evaluated according to literacy levels. Results: an abnormal PSA, a suspicious DRE, or both were present in 73.2%, 19.7%, and 7.1% of those men who underwent biopsy, respectively. PCa was diagnosed in 652 men (3.7%). Previous PSAs or DREs were less common among illiterate men (p < 0.0001). Additionally, illiterate men were less prone to attend to further evaluations due to an abnormal PSA or DRE (p < 0.0001). PSA levels > 10 mg/mL (p = 0.03), clinical stage > T2a (p = 0.005), and biopsy Gleason > 7 (p = 0.02) were more common among illiterate men. Conclusions: In a screened population, literacy levels were associated with prior PCa evaluations and with compliance with screening protocols. Illiterate men were at higher risk of being diagnosed with more advanced and aggressive PCa.

show abstract

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening

Cited by 60 publications

References 24 publications

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Association between Literacy, Compliance with Prostate Cancer Screening, and Cancer Aggressiveness: Results from a Brazilian Screening Study

Contact Info

Product

Resources

About